BIOVECTRA Named to True North List of Leading Canadian Companies

Posted on by BIOVECTRA

 

CHARLOTTETOWN, PEI – BIOVECTRA was recently named to Communitech’s True North list as one of Canada’s high performing tech companies that has a promising growth trajectory.

Team True North is a roster of Canadian innovation companies shown by verified data to have the highest probability of reaching $1B in revenue. As global markets experience volatility, past experience has shown that strong global leaders become even stronger. Team True North represents the 1 per cent of highest-performing global private companies in Canada.

“Joining Team True North is a milestone on BIOVECTRA’s growth journey as we continue expanding our offer to global biotechnology and pharmaceutical companies,” shares Oliver Technow, CEO BIOVECTRA. “Our business growth is expected to accelerate further as BIOVECTRA expands into mRNA technology in 2023, delivering the next generation of patient care solutions to our roster of global clients and doing our part to help expand Canada’s biomanufacturing capacity.”

BIOVECTRA was the sole Atlantic Canadian based company that made this year’s True North list. With a fifty-year history as an innovator in the region, the company has nearly tripled revenues and doubled its workforce over the last five years. In 2021 it was also named one of Canada’s Top 100 Employers.


About BIOVECTRA:
We are a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, small molecules, bioreagents, and pDNA and MRNA manufacturing.  Flexibility, creativity, process optimization and compliance are at the heart of our method. With more than 50 years of experience, 600 employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.

About Communitech:
Established in 1997 in Waterloo Region, Communitech was built by tech founders who saw the need for a community of support to help ensure the future prosperity of Canada. Today, Communitech is Canada’s leading innovation hub, supporting a community of more than 1,200 founders by providing accelerated opportunities to access talent, capital and sales.

Helpful Links:
www.biovectra.com

Team True North – Communitech

Contact

Bobbi Jo Walker
Director, Corporate Communications
BIOVECTRA
902-218-7649

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors